Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.
Daniela Kroshinsky, MD, MPH
Advertisement
Daniela Kroshinsky, MD, MPH, works in the Department of Dermatology at the Duke University School of Medicine.
Articles by Daniela Kroshinsky, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
2
INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD
3
First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD
4
AI Reshaping Diabetes Care From Nutrition to Clinical Decisions
5